CSL continues to provide medicines to patients around the world.

“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies

King of Prussia, Pa. and Sioux Falls, S.D., April 8, 2020

COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology,
on-track for clinical evaluation as early as summer

Osaka, JAPAN, and King of Prussia, PA, USA

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.

HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.

Now approved by Health Canada: Hizentra® (Subcutaneous Immunoglobulin [Human] 20% Liquid) for the Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for maintenance therapy

Ottawa – CSL Behring has shipped more than 10 million international units (IUs) of its medicines to treat hemophilia A to the WFH Global Alliance for Progress (GAP)Program in recognition of World Hemophilia Day.